Department of Otolaryngology, Head and Neck Surgery, University Hospital Giessen and Marburg GmbH, Campus Marburg, Baldingerstrasse, 35033 Marburg, Germany.
Anticancer Res. 2013 Jan;33(1):249-52.
Surgical treatment remains the mainstay therapy for recurrence of head and neck cancer after previous radiotherapy. In inoperable cases, interstitial high-dose rate brachytherapy is a treatment option for local dose escalation.
A retrospective analysis of all patients who were treated solely with brachytherapy for advanced non-resectable recurrences of squamous cell carcinomas of the head and neck and who previously received radiotherapy was performed.
A total of 12 patients with advanced recurrences were treated with interstitial brachytherapy with a fraction dose of 2-3 Gy and a total focal dose of 20-33 Gy. The shortest survival after brachytherapy was 4 weeks. The longest clinical course without evidence of local recurrence is 4 years and 11 months.
In selected cases brachytherapy can be used as the last-line or palliative therapy for patients with advanced recurrence head and neck carcinomas. Possible complications and the reduction of quality of life due to tracheostomy should be considered.
对于头颈部癌症放疗后复发的患者，手术治疗仍然是主要治疗方法。对于无法手术的患者，间质内高剂量率近距离放疗是局部剂量升级的一种治疗选择。
对所有仅接受近距离放疗治疗无法切除的晚期复发头颈部鳞状细胞癌且既往接受过放疗的患者进行回顾性分析。
共 12 例晚期复发患者接受了间质内近距离放疗，单次剂量为 2-3Gy，总焦点剂量为 20-33Gy。最短的生存期为 4 周，最长的无局部复发临床过程为 4 年 11 个月。
在选择合适的病例中，近距离放疗可作为晚期复发头颈部癌患者的一线或姑息治疗方法。应考虑可能出现的并发症以及气管造口术导致的生活质量下降。
